UNSPSC 51323205: Cerivastatin sodium

This classification denotes a hmg-coa reductase inhibitor with the molecular formula C26H33FNO5.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6Q18G1060S, chemically known as 6-heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, (s-(r*,s*-(e)))- but more generally known as cerivastatin sodium, which bears US NIH Compound Identifier 446156.

UNSPSC 51323205 Cerivastatin sodium is a Commodity code under which state and local governments procure generic pharmaceutical products, particularly statin medications and other critical care drugs for emergency response and health benefit programs. The scope of work covers direct supply of finished pharmaceutical products to fire departments, health agencies, and multistate purchasing cooperatives, with vendors required to meet FDA compliance, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, and specific expiration-date and shelf-life guarantees. Issuing bodies include city purchasing departments (fire rescue operations), state health agencies, and regional cooperative purchasing alliances serving multiple jurisdictions. The City of Tampa's fire rescue program and the Texas Health and Human Services Commission represent the primary recent buyers, though the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) broadens reach across state and local facilities in Minnesota and Oregon through an RFP structure.

Recent activity concentrates in the South and Midwest. The City of Tampa issued IFB 26P00188 in April 2026 seeking Advanced Life Support Medications including statin and cardiac-care products (response deadline April 8, 2026; estimated contract value $40,000), with a Small Local Business Enterprise sheltered-market 5 percent bid discount available. The Texas Health and Human Services Commission released an exploratory RFI in early April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program without formal competitive solicitation parameters. MMCAP's RFP (S1070000015802, due March 26, 2026) targets generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with contract effectiveness July 1, 2026. All recent opportunities require detailed product information (NDC codes, UPCs, manufacturing locations), comprehensive insurance coverage, and vendor-wholesaler relationship documentation; pricing evaluation heavily weights cost competitiveness (75 percent at MMCAP) against administrative fee and compliance criteria.